This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Generex: What Happens in India, Stays in India

On March 25, 2008, Generex announced receipt of a "commercial order" for 210,000 canisters of Oral-lyn from Shreya.

"We are pleased to anticipate the commercialization of our flagship product in a major market like India and the attendant revenue," said Generex CEO Gluskin in the March 25, 2008 press release.

Generex and Shreya announced the commercial launch of Oral-lyn in India under the brand name Oral Recosulin in November 2008. By January 2009, Oral Recosulin was available for sale and over 50 doctors in India were prescribing the product, according to Generex's 10Q filed with the SEC for the quarter ended Jan. 31, 2009.

On March 11, 2009, Generex provided investors with a sales update on Oral Recosulin (Oral-lyn) in India, announcing that Shreya had "procured Oral Recosulin orders from more than 60 doctors for over 100 patients."

Gluskin, in the same press release, stated, "We believe that the rapid progress that our licensee has made in India reflects the demand for a pain-free insulin product."

That "rapid progress," however, wasn't generating any Oral Recosulin revenue for Generex. While Generex claimed in early 2009 that Indian doctors were prescribing Oral Recosulin to their diabetes patients, as of the company's last quarterly financial update in March, Generex has not shown any record of sales from Oral Recosulin in India, nor any of the other three countries -- Ecuador, Lebanon and Algeria -- where the product is allegedly approved for sale.

Oral-lyn yanked in India

The most probable reason for why India was not generating any Oral-lyn revenue for Generex was that the Indian government revoked Oral-lyn's approval soon after the product's launch.

On March 26, 2009, the Drugs Controller General of India (DCGI) ordered Generex and Shreya to halt the importation and sale of Oral-lyn.

The Indian government took action against Oral-lyn after an investigation by Mint, an Indian business newspaper, alleging that Generex and Shreya violated Indian drug laws by seeking approval without conducting mandatory human clinical trials in India.
3 of 5

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
GNBT $0.01 2.94%
LLY $86.50 5.44%
NVO $56.19 2.22%
MNKD $2.13 6.50%
SNY $44.05 -0.38%


Chart of I:DJI
DOW 17,888.35 +168.43 0.95%
S&P 500 2,102.63 +22.22 1.07%
NASDAQ 5,156.3060 +47.64 0.93%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs